<DOC>
	<DOCNO>NCT00002766</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know regimen combination chemotherapy effective acute lymphoblastic leukemia , lymphoblastic lymphoma , chronic myelogenous leukemia . PURPOSE : This randomized phase III trial study two different chemotherapy regimen compare see well work treat adult acute lymphoblastic leukemia , lymphoblastic lymphoma , chronic myelogenous leukemia .</brief_summary>
	<brief_title>Comparison Two Combination Chemotherapy Regimens Treating Adults With Previously Untreated Leukemia Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare incidence complete remission ( CR ) follow induction ALL-2 regimen ( cytarabine high-dose mitoxantrone ) vs L-20 regimen ( vincristine prednisone ) previously untreated adult patient acute lymphoblastic leukemia ( ALL ) , lymphoblastic lymphoma , lymphoid blast crisis chronic myelogenous leukemia . - Compare time CR , length hospital stay , efficacy treatment Philadelphia chromosome-positive ALL , proportion patient achieve durable ( great 5 year ) remission treatment regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate institution antecedent lymphoid blast crisis chronic myelogenous leukemia ( yes v ) . Patients randomize one two treatment arm . Arm I : - Patients receive induction therapy consist cytarabine IV 3 hour day 1-5 high-dose mitoxantrone IV day 3 methotrexate intrathecally day 2 4 . Patients receive sargramostim ( GM-CSF ) subcutaneously IV 4 hour begin day 7 continue blood count recover . - At 7-14 day follow induction therapy , patient receive consolidation therapy consist vincristine IV day 1 , 8 , 15 , 22 , 29 , oral prednisone 2-3 time daily day 1-30 methotrexate intrathecally day 8 , 15 , 22 , 29 . - At 2-3 week follow last dose vincristine , patient receive additional course consolidation therapy consist cyclophosphamide IV day 1 GM-CSF subcutaneously begin day 3 continue blood count recover . - At 3-4 week follow second consolidation course , patient receive third course consolidation therapy consist cytarabine IV bolus day 1 follow continuous infusion cytarabine day 1-4 etoposide IV 1 hour day 1-3 methotrexate intrathecally day 2 4 . Patients receive GM-CSF subcutaneously begin day 6 continue blood count recover . - Following recovery third consolidation course , patient receive fourth consolidation course consist pegaspargase IV intramuscularly ( IM ) day 1 . - Following recovery consolidation therapy patient receive 2 sequence maintenance therapy sequence one consist vincristine IV day 1 8 , oral prednisone 2-3 time daily day 1-8 , doxorubicin IV day 15 , oral mercaptopurine 2-3 time daily day 36-64 , oral methotrexate day 39 , 46 , 53 , 60 , dactinomycin IV day 85 , methotrexate intrathecally day 36 43 . - At 2 week follow sequence one maintenance therapy , patient receive sequence two consist regimen first sequence addition cyclophosphamide IV carmustine IV day 15 . - Patients CNS involvement receive whole brain radiotherapy addition chemotherapy regimen . Arm II : - Patients receive induction therapy consist vincristine IV day 1 , 8 , 15 , 22 , 29 , oral prednisone 2-3 time daily day 1-29 , cyclophosphamide IV day 5 , doxorubicin IV day 23-25 42 , methotrexate intrathecally day 3 , 5 , 13 , 16 , 32 , 34 GM-CSF subcutaneously IV 4 hour begin day 7 27 continue blood count recover . - At approximately 3 week follow induction therapy , patient receive consolidation therapy consist cytarabine IV bolus day 1 follow continuous infusion cytarabine day 1-5 , daunorubicin IV day 1-3 methotrexate intrathecally day 2 4 . Patients receive GM-CSF subcutaneously begin day 7 continue blood count recover . - At 6-8 week follow first course consolidation therapy , patient receive second consolidation course consist cytarabine IV bolus day 1 follow continuous infusion cytarabine day 1-4 methotrexate IV day 1-4 methotrexate intrathecally day 2 4 . Patients receive GM-CSF subcutaneously begin day 6 continue blood count recover . - At 6-8 week follow second course consolidation therapy , patient receive third consolidation course consist pegaspargase IV IM day 1 . - At 3-4 week follow third course consolidation therapy , patient receive fourth consolidation course consist cyclophosphamide IV day 1 . - At 3 week follow completion consolidation therapy , patient receive maintenance regimen Arm I . Treatment continue patient achieve complete response . Patients arm receive alternate sequence maintenance therapy 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one follow malignancy : Acute lymphoblastic leukemia ( ALL ) B Tcell lineage Philadelphia chromosomepositive ALL eligible Lymphoblastic lymphoma Chronic myelogenous leukemia lymphoid blast crisis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 20100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL Glucocorticoids high bilirubin allow prior entry , principal investigator 's discretion Renal : Creatinine great 2.0 mg/dL Glucocorticoids renal radiotherapy high creatinine allow prior entry , principal investigator 's discretion Cardiovascular : Left ventricular ejection fraction least 50 % Other : Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy Chemotherapy No prior chemotherapy Endocrine therapy No prior endocrine therapy Radiotherapy No prior radiotherapy Surgery No prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
	<keyword>T-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>B-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
</DOC>